Jaguar Health establishes INAD file with FDA’s CVM for crofelemer

Jaguar Health has established a new Investigational New Animal Drug file with the Center for Veterinary Medicine of the U.S. Food and Drug Administration for the company’s novel plant-based prescription drug crofelemer to treat general, non-infectious diarrhea in dogs. Crofelemer delayed-release tablets, under the name Canalevia-CA1, received conditional approval in December 2021 from the FDA for the treatment of chemotherapy-induced diarrhea in dogs. Jaguar previously issued results from a multicenter, randomized, double-blind, controlled proof-of-concept study that assessed the efficacy of crofelemer administered orally in alleviating clinical signs associated with secretory diarrhea in dogs. The study results showed that crofelemer was superior to placebo.